Cargando…

Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation

INTRODUCTION: The minimal residual disease (MRD) status plays a crucial role in the treatment of acute lymphoblastic leukemia (ALL) and is currently used in most therapeutic protocols to guide the appropriate therapeutic decision. Therefore, it is imperative that laboratories offer accurate and reli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikoma-Colturato, Maura R.V., Beltrame, Miriam P., Furtado, Felipe M., Pimenta, Glicinia, da Costa, Elaine Sobral, Azambuja, Ana Paula, Malvezzi, Mariester, Yamamoto, Mihoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2021
Materias:	Special Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446261/ https://www.ncbi.nlm.nih.gov/pubmed/33281111 http://dx.doi.org/10.1016/j.htct.2020.09.148

Ejemplares similares

Updating recommendations of the Brazilian Group of Flow Cytometry (GBCFLUX) for diagnosis of acute leukemias using four-color flow cytometry panels
por: Beltrame, Míriam P., et al.
Publicado: (2021)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Multicentric standardization of minimal/measurable residual disease in B‐cell precursor acute lymphoblastic leukaemia using next‐generation flow cytometry in a low/middle‐level income country
por: Ikoma‐Colturato, Maura R. V., et al.
Publicado: (2022)

Paroxysmal nocturnal hemoglobinuria clone in 103 Brazilian patients: diagnosis and classification
por: de Azambuja, Ana Paula, et al.
Publicado: (2015)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
por: Pessach, Ilias, et al.
Publicado: (2022)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges
por: Riva, Giovanni, et al.
Publicado: (2021)

Pharmacogenetic testing for thiopurine drugs in Brazilian acute lymphoblastic leukemia patients
por: Suarez-Kurtz, Guilherme, et al.
Publicado: (2023)

Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
por: Tierens, Anne, et al.
Publicado: (2021)

Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting
por: Modvig, S., et al.
Publicado: (2020)

P383: THE NEXT-GENERATION SEQUENCING (NGS) BASED MRD ASSESSMENT COULD BETTER PREDICT RELAPSE THAN MULTIPARAMETER FLOW CYTOMETRY (MFC) IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Yan, Nan, et al.
Publicado: (2023)

Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
por: Oliveira, Elen, et al.
Publicado: (2022)

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
por: Kotrová, Michaela, et al.
Publicado: (2022)

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
por: Kantarjian, Hagop M., et al.
Publicado: (2023)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia
por: Weng, X-Q, et al.
Publicado: (2013)

Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma – a diagnostic challenge solved by flow cytometry
por: Loureiro, Aleyde Diniz, et al.
Publicado: (2017)

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
por: van Outersterp, Inge, et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Color-scalable flow cytometry with Raman tags
por: Nishiyama, Ryo, et al.
Publicado: (2023)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

Are the review criteria for automated complete blood counts of the International Society of Laboratory Hematology suitable for all hematology laboratories?
por: Comar, Samuel Ricardo, et al.
Publicado: (2014)

To follow or not to follow the recommendations regarding microscopic analysis of the Clinical and Laboratory Standards Institute H20-A2 to validate the criteria for blood smear review?
por: Comar, Samuel Ricardo, et al.
Publicado: (2015)

Erratum to “Are the review criteria for automated complete blood counts of the International Society of Laboratory Hematology suitable for all hematology laboratories?” [Rev. Bras. Hematol. Hemoter. 2014;36(3):219–225]
por: Comar, Samuel Ricardo, et al.
Publicado: (2014)

Evaluation of criteria of manual blood smear review following automated complete blood counts in a large university hospital
por: Comar, Samuel Ricardo, et al.
Publicado: (2017)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2021)

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis
por: Bhasin, Swati S., et al.
Publicado: (2023)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
por: Deng, Shiyu, et al.
Publicado: (2023)

Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD
por: Schultz, Liora, et al.
Publicado: (2023)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
por: chen, M., et al.
Publicado: (2022)

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)
por: Weber, Axel, et al.
Publicado: (2012)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_16ousj7dk6dup7lv99prfov6vg